Skip to main content
. 2013 Feb 18;14:40. doi: 10.1186/1471-2369-14-40

Table 2.

Dose of lanthanum carbonate at the end of the dose-titration phase; safety set

Dose, mg/day Dose-titration phase (n= 39) Parallel-group phase
Lanthanum carbonate (n= 10) Placebo (n= 11)
375
5 (12.8)
1 (10.0)
0 (0.0)
750
11 (28.2)
3 (30.0)
4 (36.4)
1500
14 (35.9)
3 (30.0)
4 (36.4)
2250 9 (23.1) 3 (30.0) 3 (27.3)

Data are presented as n (%).